About this trial
The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy.
The blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene.
As new treatments are developed, a clear understanding of the natural history of disease progression of BEST1 VMD is necessary. The goals of this natural history study are to:
1. Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutation(s). 2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD. 3. Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment 4. Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Ability to provide informed consent
Diagnosis of BEST1-associated VMD by study physician, who are trained retinal specialists in the university clinic Must be able to commit to 4 follow-up study visits (3 years)
Disqualifiers
Systemic condition that prevents the participant from undergoing the exams
Trial population
Patients are expected to present to the clinic at all age groups; enrollment of subjects \<18 years of age will be obtained by informed consent in the company of a parent or legal guardian. There will also be no gender-or ethnic/racial specific inclusion criteria. The enrollment of non-English speaking subjects is not expected.
Trial design
Cohort
Prospective
Treatments tested in this trial
Natural History Study
Other interventionLongitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
Treatment groups
Trial outcomes
Primary outcomes
Medmont Dark Adapted Chromatic (DAC) Automated Perimeter
Full-field electroretinogram (ERG)
ERG conducted under International Society for Clinical Electrophysiology of Vision (ISCEV) Protocol.
Electroocoulogram (EOG)
EOG conducted under International Society for Clinical Electrophysiology of Vision (ISCEV) Protocol
Optical Coherence Tomography (OCT)
Secondary outcomes
Best-corrected Visual Acuity (BCVA)
Color Fundus Photos
Macular Integrity Assessment (MAIA) Microperimetry
Goldman Kinetic Visual Field
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Columbia University
Lead sponsor
Universität Tübingen
Collaborator
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Collaborator
National Eye Institute (NEI)
Collaborator